Acuity Says IND Gets FDA Ok
Acuity Pharmaceuticals has said that its investigational new drug application for its siRNA-based treatment for age-related macular degeneration has been approved by US regulators.
According to a statement from Acuity’s president and CEO Dale Pfost, “the FDA usually reviews INDs in one month, and in the absence of notification to the contrary an IND may open and recruitment of patients commence. Acuity’s IND is now open, and patients are planned to begin to be treated in October,” he added.